KindredBio Announces the Filing of an INAD for Laminitis in Horses

KIND-005 is expected to be a major new therapy for the treatment of laminitis in horses.

SAN FRANCISCO, California. (March 26, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-005. KIND-005 inhibits a biological pathway that plays a critical role in the pathogenesis of equine laminitis.

Read more